Targeting Angiogenesis in Bladder Cancer

被引：31

作者：

Elfiky, Aymen A. ^{[1
]}

Rosenberg, Jonathan E. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA

来源：

CURRENT ONCOLOGY REPORTS | 2009年 / 11卷 / 03期

关键词：

ENDOTHELIAL GROWTH-FACTOR; TRANSITIONAL-CELL CARCINOMA; RECEPTOR MONOCLONAL-ANTIBODY; ONCOLOGY-GROUP ECOG; MICROVESSEL DENSITY; FACTOR EXPRESSION; INTERSTITIAL HYPERTENSION; INHIBITOR TNP-470; PROGNOSTIC VALUE; BREAST-CANCER;

D O I：

10.1007/s11912-009-0034-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In most cases, death from bladder cancer results from metastatic disease. Understanding the closely linked mechanisms of invasion, metastasis, and angiogenesis in bladder cancer has allowed development of new therapeutic strategies that may lead to improvements in patient survival. Vascular endothelial growth factor levels appear to be prognostic for outcomes in advanced bladder cancer, and preclinical evaluation of angiogenesis inhibition demonstrates anticancer activity. Antiangiogenic agents such as sunitinib, sorafenib, and bevacizumab are being tested in advanced bladder cancer. This review highlights the key developments in antiangiogenic therapy as it relates to bladder cancer treatment.

引用

页码：244 / 249

页数：6

共 58 条

[1] Neoadjuvant chemotherapy in invasive bladder cancer:: Update of a systematic review and meta-analysis of individual patient data [J].

Abol-Enein, H ;

Bassi, P ;

Boyer, M ;

Coppin, CML ;

Cortesi, E ;

Grossman, HB ;

Hall, RR ;

Horwich, A ;

Malmström, PU ;

Martinez-Piñeiro, JA ;

Sengelov, L ;

Sherif, A ;

Wallace, DMA ;

Bono, AV ;

Goebell, PJ ;

Groshen, S ;

Torti, FM ;

Clarke, NW ;

Roberts, JT ;

Sylvester, R ;

Parmar, MKB ;

Stewart, LA ;

Tierney, JF ;

Vale, CL .

EUROPEAN UROLOGY, 2005, 48 (02) :202-206

[2] EXPRESSION OF BASIC FIBROBLAST GROWTH-FACTOR AND ITS RECEPTOR IN AN INVASIVE BLADDER-CARCINOMA CELL-LINE [J].

ALLEN, LE ;

MAHER, PA .

JOURNAL OF CELLULAR PHYSIOLOGY, 1993, 155 (02) :368-375

[3] Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder [J].

Beecken, WD ;

Engl, T ;

Hofmann, J ;

Jonas, D ;

Blaheta, R .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2005, 9 (03) :655-661

[4]

Bellmunt J, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.07.0888

[5] Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer [J].

Bernardini, S ;

Fauconnet, S ;

Chabannes, E ;

Henry, PC ;

Adessi, G ;

Bittard, H .

JOURNAL OF UROLOGY, 2001, 166 (04) :1275-1279

[6] ANGIOGENESIS IN BLADDER-CANCER - RELATIONSHIP BETWEEN MICROVESSEL DENSITY AND TUMOR PROGNOSIS [J].

BOCHNER, BH ;

COTE, RJ ;

WEIDNER, N ;

GROSHEN, S ;

CHEN, SC ;

SKINNER, DG ;

NICHOLS, PW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) :1603-1612

[7]

BOUCHER Y, 1991, CANCER RES, V51, P6691

[8]

Campbell SC, 1998, CANCER RES, V58, P1298

[9] Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. [J].

Canoglu A. ;

Gögüş C. ;

Bedük Y. ;

Orhan D. ;

Tulunay O. ;

Baltaci S. .

International Urology and Nephrology, 2004, 36 (3) :401-405

[10]

Crew JP, 1997, CANCER RES, V57, P5281

← 1 2 3 4 5 6 →